PIRS Pieris Pharmaceuticals
- 17.0000
- +1.9500+12.96%
Pieris Pharmaceuticals News
ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition of Pieris Pharmaceuticals, Inc.
Shareholder Alert: Ademi LLP Investigates Whether Pieris Pharmaceuticals, Inc. Has Obtained a Fair Price for Its Public Shareholders
Trending Stocks Today | Nuzee Surges 273.78%
Sector Update: Health Care Stocks Advance in Afternoon Trading
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results
Pieris Pharma Surges on All-stock Merger Deal
Pieris Pharma Shares Double on Buyout Offer From Palvella Therapeutics
Express News | Pieris Pharmaceuticals Shares Resume Trade
Express News | Pieris Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 93.2%
Traders Digest Alphabet, Tesla Results, Fueling Premarket Losses for US Equity Futures
Merger News Boosts Pieris (PIRS) Stock In Pre-Market Trading
Express News | Pieris Pharmaceuticals Shares Are Trading Higher After the Company Announced That the Company Entered Into a Definitive Merger Agreement With Palvella Therapeutics
Top Premarket Gainers
Express News | Pieris Pharmaceuticals- Combined Company to Be Led by Wes Kaupinen & Other Members of Palvella Management Team
Express News | Pieris Pharmaceuticals - Pre-Merger Palvella Stockholders Will Own Approximately 82% of Combined Company on a Pro Forma Basis
Express News | Pieris Pharmaceuticals - Pre-Merger Pieris Stockholders Will Own About 18% of Combined Company
Express News | Pieris Pharmaceuticals Inc - Palvella to Become Wholly-Owned Unit of Co
Express News | Pieris Pharmaceuticals Inc - to Issue Shares of Pieris Common Stock to Pre-Merger Palvella Stockholders as Merger Consideration
Palvella Therapeutics And Pieris Pharmaceuticals To Merge, Creating A Nasdaq-Listed Entity With $80.5M Cash To Drive Development Of Novel Skin Disease Therapies
Analysis
Price Target
No Data
